Stay updated on CIN-107 Study in Uncontrolled Hypertension Clinical Trial
Sign up to get notified when there's something new on the CIN-107 Study in Uncontrolled Hypertension Clinical Trial page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2F92iNe3AvEGXMEAY8pOM7ZC-e2fw.uncropped.jpg&w=3840&q=75)
Latest updates to the CIN-107 Study in Uncontrolled Hypertension Clinical Trial page
- CheckyesterdayNo Change Detected
- Check2 days agoNo Change Detected
- Check3 days agoNo Change Detected
- Check4 days agoChange DetectedThe study has expanded to include 63 locations, and the revision has been updated from v2.9.7 to v2.10.0.SummaryDifference0.4%
- Check5 days agoNo Change Detected
- Check11 days agoChange DetectedThe website has been updated to Revision v2.9.7 from v2.9.6.SummaryDifference0.1%
- Check25 days agoChange DetectedThe value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check30 days agoChange DetectedThe value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check31 days agoChange DetectedThe value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check32 days agoChange DetectedThe value 'Show more Show more Revision: v2.9.0' has recently changed to 'Show less MedlinePlus Genetics related topics: Hypertension MedlinePlus related topics: High Blood Pressure FDA Drug and Device Resources Show less Design Details Primary Purpose : Treatment Allocation : Randomized Interventional Model : Parallel Assignment Masking : Quadruple ( Participant Care Provider Investigator Outcomes Assessor ) Arms and Interventions Participant Group/Arm Intervention/Treatment Experimental : CIN-107 0.5 mg Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient will receive the highest dose of CIN-107 (2 mg) and discontinue their background antihypertensive agent(s) for 4 weeks Drug : CIN-107 CIN-107 tablets by mouth once daily Other Names: Baxdrostat Experimental : CIN-107 1 mg Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient will receive the highest dose of CIN-107 (2 mg) and discontinue their background antihypertensive agent(s) for 4 weeks Drug : CIN-107 CIN-107 tablets by mouth once daily Other Names: Baxdrostat Experimental : CIN-107 2 mg Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient may remain on CIN-107 (2 mg) and discontinue their background antihypertensive agent(s) for 4 weeks or withdraw study participation depending on BP control Drug : CIN-107 CIN-107 tablets by mouth once daily Other Names: Baxdrostat Placebo Comparator : Placebo Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient will receive the highest dose of CIN-107 (2mg) and discontinue their background antihypertensive agent(s) for 4 weeks Drug : Placebo Placebo tablets by mouth once daily Primary Outcome Measures Outcome Measure Measure Description Time Frame Change From Baseline in Mean Seated Systolic BP (SBP) The primary efficacy endpoint was the change from baseline in mean seated SBP after 8 weeks of treatment in patients with uncontrolled HTN (Part 1). 8 weeks Secondary Outcome Measures Outcome Measure Measure Description Time Frame Change From Baseline in Mean Seated Diastolic BP (DBP) The change from baseline in mean seated DBP with CIN-107 compared to placebo after 8 weeks of treatment (Part 1) 8 weeks Change From Baseline in 24-hour Urine Aldosterone The change from baseline in 24-hour urine aldosterone levels with CIN 107 compared to placebo after 8 weeks of treatment (Part 1) 8 weeks Change From Baseline in 24-hour Serum Aldosterone The change from baseline in 24-hour serum aldosterone levels with CIN 107 compared to placebo after 8 weeks of treatment (Part 1) 8 weeks Percentage of Patients Achieving a Mean Seated SBP <130 mmHg The percentage of patients achieving a mean seated SBP <130 mmHg ('responders') with CIN-107 compared to placebo after 8 weeks of treatment (Part 1; Weeks 1 to 8) 8 weeks Change From Baseline in 24-hour Urine Renin The change from baseline in 24-hour urine renin levels with CIN-107 compared to placebo after 8 weeks of treatment (Part 1) 8 weeks Change From Baseline in 24-hour Serum Renin The change from baseline in 24-hour serum renin levels with CIN-107 compared to placebo after 8 weeks of treatment (Part 1) 8 weeks Additional Relevant MeSH Terms Vascular Diseases Cardiovascular Diseases Hypertension Plan to Share Individual Participant Data (IPD)? No Studies a U.S. FDA-Regulated Drug Product Yes Studies a U.S. FDA-Regulated Device Product No Study Documents Provided by CinCor Pharma, Inc. Study Protocol [ PDF , 12MB, 2022-02-25 ] Statistical Analysis Plan [ PDF , 6.68MB, 2022-10-07 ] Revision: v2.9.1' represents the recent change on the webpage.SummaryDifference28%
Stay in the know with updates to CIN-107 Study in Uncontrolled Hypertension Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CIN-107 Study in Uncontrolled Hypertension Clinical Trial page.